Patents by Inventor Richard Kolodner

Richard Kolodner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 3-hydroxy-quinazoline-2,4-dione derivatives and their use as nuclease modulators
    Patent number: 11253521
    Abstract: Described inter alia are compounds according to formula (I): or a pharmaceutically acceptable salt thereof, and uses in methods for the modulation of flap endonuclease 1 (FEN1), Xeroderma Pigmentosum Complementation Group G protein (XPG), Exonuclease 1 (EXO1) and/or GEN1.
    Type: Grant
    Filed: September 26, 2016
    Date of Patent: February 22, 2022
    Assignee: Ludwig Institute for Cancer Research Ltd
    Inventors: Timothy Gahman, Andrew Shiau, Richard Kolodner
  • 3-HYDROXY-QUINAZOLINE-2,4-DIONE DERIVATIVES AND THEIR USE AS NUCLEASE MODULATORS
    Publication number: 20200237763
    Abstract: Described inter alia are compounds according to formula (I): or a pharmaceutically acceptable salt thereof, and uses in methods for the modulation of flap endonuclease 1 (FEN1), Xeroderma Pigmentosum Complementation Group G protein (XPG), Exonuclease 1 (EXO1) and/or GEN1.
    Type: Application
    Filed: September 26, 2016
    Publication date: July 30, 2020
    Inventors: Timothy Gahman, Andrew Shiau, Richard Kolodner
  • Method of Detection of Alterations in MSH5
    Publication number: 20080199876
    Abstract: We have now discovered that mammals have a DNA gene analogous to that existing in bacteria. MSH5 defects or alterations in this mismatch repair pathway in a mammal, such as a human can be diagnostic of a predisposition to cancer, and prognostic for a particular cancer. We have discovered and sequenced MSH5 in this in a number of mammals, including humans. This gene can be used in assays, to express gene product, for drug screens, and therapeutically.
    Type: Application
    Filed: April 14, 2008
    Publication date: August 21, 2008
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Richard Kolodner, Nena Winand
  • Method of detection of alterations in MSH5
    Patent number: 7374914
    Abstract: We have now discovered that mammals have a DNA gene analogous to that existing in bacteria. MSH5 defects or alterations in this mismatch repair pathway in a mammal, such as a human, can be diagnostic of a predisposition to cancer, and prognostic for a particular cancer: We have discovered and sequenced MSH5 in a number of mammals, including humans. This gene can be used in assays, to express gene product, for drug screens, and therapeutically.
    Type: Grant
    Filed: October 7, 2003
    Date of Patent: May 20, 2008
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Richard Kolodner, Nena Winand
  • Methods for modulating the activity of MSH-5
    Publication number: 20050153922
    Abstract: An animal, e.g., transgenic mouse, in which the MSH5 gene is misexpressed. The animal is useful for screening treatments for a number of conditions. Methods for identifying contraceptive agents are also described.
    Type: Application
    Filed: December 1, 2004
    Publication date: July 14, 2005
    Applicants: Albert Einstein College of Medicine of Yeshiva University, Dana-Farber Cancer Institute, Inc.
    Inventors: Winfried Edelmann, Richard Kolodner, Jeffrey Pollard, Raju Kucherlapati
  • Method of detection of alterations in MSH5
    Publication number: 20040115715
    Abstract: We have now discovered that mammals, have a DNA gene analogous to that existing in bacteria. MSH5 defects or alterations in this mismatch repair pathway in a mammal, such as a human can be diagnostic of a predisposition to cancer, and prognostic for a particular cancer.
    Type: Application
    Filed: October 7, 2003
    Publication date: June 17, 2004
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Richard Kolodner, Nena Winand
  • Isolated cryopyrins, nucleic acid molecules encoding these, and use thereof
    Publication number: 20040038224
    Abstract: The invention involves isolation of a new class of proteins, referred to hereafter as the cryopyrins. Also described are the isolated nucleic acid molecules involved in their expression. The inventive molecules are useful in diagnosing and treating inflammatory diseases, such as FCU/FCAS and MWS.
    Type: Application
    Filed: October 4, 2002
    Publication date: February 26, 2004
    Inventors: Richard Kolodner, Hal Hoffman
  • Method of detection of alterations in MSH5
    Patent number: 6670460
    Abstract: We have now discovered that mammals, have a DNA gene analogous to that existing in bacteria. MSH5 defects or alterations in this mismatch repair pathway in a mammal, such as a human can be diagnostic of a predisposition to cancer, and prognostic for a particular cancer. We have discovered and sequenced MSH5 in this in a number of mammals, including humans. This gene, can be used in assays, to express gene product, for drug screens, and therapeutically.
    Type: Grant
    Filed: December 22, 1999
    Date of Patent: December 30, 2003
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Richard Kolodner, Nena Winand
  • METHOD OF DETECTION OF ALTERATIONS IN MSH5
    Publication number: 20020187469
    Abstract: We have now discovered that mammals, have a DNA gene analogous to that existing in bacteria. MSH5 defects or alterations in this mismatch repair pathway in a mammal, such as a human can be diagnostic of a predisposition to cancer, and prognostic for a particular cancer.
    Type: Application
    Filed: December 22, 1999
    Publication date: December 12, 2002
    Inventors: RICHARD KOLODNER, NENA WINAND
  • Detection of mismatches by cleavage of nucleic acid heteroduplexes
    Patent number: 5824471
    Abstract: Novel methods and kits for detecting mismatches in nucleic acids using one or more resolvase enzymes. These methods can be used in medical procedures or research, veterinary procedures or research, agricultural applications, forensics, and paternity testing. For example, in forensics and paternity testing, methods of the invention can replace or complement RFLP mapping.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: October 20, 1998
    Assignees: Brigham and Women's Hospital, Dana-Farber Cancer Institute
    Inventors: Robert Mashal, Jeffrey Sklar, Richard Kolodner